Literature DB >> 25084696

DNA polymorphisms at BCL11A, HBS1L-MYB and Xmn1-HBG2 site loci associated with fetal hemoglobin levels in sickle cell anemia patients from Northern Brazil.

Greice Lemos Cardoso1, Isabela Guerreiro Diniz1, Aylla Núbia Lima Martins da Silva1, Daniele Almeida Cunha1, Josivaldo Soares da Silva Junior1, Camila Tavares Carvalho Uchôa1, Sidney Emanuel Batista dos Santos1, Saide Maria Sarmento Trindade2, Maria do Socorro de Oliveira Cardoso2, João Farias Guerreiro1.   

Abstract

Increased levels of fetal hemoglobin (HbF, α2γ2) may reduce sickle cell anemia severity due to its ability to inhibit HbS polymerization and also reduce the mean corpuscular HbS concentration. We have investigated the influence of three known major loci on the HbF trait (HBG2, rs748214; BCL11A, rs4671393; and HBS1L-MYB, rs28384513, rs489544 and rs9399137) and HbF levels in SCA patients from the State of Pará, Northern Brazil. Our results showed that high levels of HbF were primarily influenced by alleles of BCL11A (rs4671393) and HMIP (rs4895441) loci, and to a lesser extent by rs748214 Gγ-globin (HBG2) gene promoter. The SNPs rs4671393 and rs4895441 explained 10% and 9.2%, respectively, of the variation in HbF levels, while 4.1% of trait variation was explained by rs748214. The results can be considered as in accordance with the pattern of ancestry displayed by the SCA patients: 39.6% European, 29.6% African and 30.8% Native American, and reinforce the suggestion that studies of association between genetic modifiers and clinical and laboratory manifestations in Brazil must be controlled by ancestry.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Brazilian patients; Fetal hemoglobin; Genetic modifier; Sickle cell anemia

Mesh:

Substances:

Year:  2014        PMID: 25084696     DOI: 10.1016/j.bcmd.2014.07.006

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  12 in total

1.  Genetic modulation of fetal hemoglobin in hydroxyurea-treated sickle cell anemia.

Authors:  Milena Magalhães Aleluia; Rayra Pereira Santiago; Caroline Conceição da Guarda; Teresa Cristina Cardoso Fonseca; Fábia Idalina Neves; Regiana Souza Quinto; Camylla Villas Boas Figueiredo; Sètondji Cocou Modeste Alexandre Yahouédéhou; Rodrigo Mota Oliveira; Júnia Raquel Dutra Ferreira; Bruno Antônio Veloso Cerqueira; Cynara Gomes Barbosa; Jacqueline Nicole Milton; Martin H Steinberg; Marilda de Souza Gonçalves
Journal:  Am J Hematol       Date:  2017-03-10       Impact factor: 10.047

2.  Protective BCL11A and HBS1L-MYB polymorphisms in a cohort of 102 Congolese patients suffering from sickle cell anemia.

Authors:  Tite Minga Mikobi; Prosper Tshilobo Lukusa; Michel Ntetani Aloni; Aimé Zola Lumaka; Didine Kinkodi Kaba; Koenraad Devriendt; Gert Matthijs; Jean Marie Mbuyi Muamba; Valérie Race
Journal:  J Clin Lab Anal       Date:  2017-03-23       Impact factor: 2.352

3.  g(HbF): a genetic model of fetal hemoglobin in sickle cell disease.

Authors:  Kate Gardner; Tony Fulford; Nicholas Silver; Helen Rooks; Nikolaos Angelis; Marlene Allman; Siana Nkya; Julie Makani; Jo Howard; Rachel Kesse-Adu; David C Rees; Sara Stuart-Smith; Tullie Yeghen; Moji Awogbade; Raphael Z Sangeda; Josephine Mgaya; Hamel Patel; Stephen Newhouse; Stephan Menzel; Swee Lay Thein
Journal:  Blood Adv       Date:  2018-02-13

4.  Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease.

Authors:  Li Liu; Alexander Pertsemlidis; Liang-Hao Ding; Michael D Story; Martin H Steinberg; Paola Sebastiani; Carolyn Hoppe; Samir K Ballas; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

5.  Existence of HbF Enhancer Haplotypes at HBS1L-MYB Intergenic Region in Transfusion-Dependent Saudi β-Thalassemia Patients.

Authors:  Cyril Cyrus; Chittibabu Vatte; J Francis Borgio; Abdullah Al-Rubaish; Shahanas Chathoth; Zaki A Nasserullah; Sana Al Jarrash; Ahmed Sulaiman; Hatem Qutub; Hassan Alsaleem; Alhusain J Alzahrani; Martin H Steinberg; Amein K Al Ali
Journal:  Biomed Res Int       Date:  2017-02-09       Impact factor: 3.411

Review 6.  Current and future alternative therapies for beta-thalassemia major.

Authors:  Edouard de Dreuzy; Kanit Bhukhai; Philippe Leboulch; Emmanuel Payen
Journal:  Biomed J       Date:  2016-04-06       Impact factor: 4.910

7.  GWAS and PheWAS of red blood cell components in a Northern Nevadan cohort.

Authors:  Robert W Read; Karen A Schlauch; Gai Elhanan; William J Metcalf; Anthony D Slonim; Ramsey Aweti; Robert Borkowski; Joseph J Grzymski
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

Review 8.  Analysis of mRNA Expression Patterns in Peripheral Blood Cells of 3 Patients With Cancer After the First Fraction of 2 Gy Irradiation: An Integrated Case Report and Systematic Review.

Authors:  Yue-Hua Nie; Xiao-Dan Liu; Ruixue Huang; Da-Fei Xie; Wen-Jun Yin; Hua Guan; Zi-Jian Yu; Ping-Kun Zhou
Journal:  Dose Response       Date:  2019-02-26       Impact factor: 2.658

9.  A systematic scoping review of the genetic ancestry of the Brazilian population.

Authors:  Aracele Maria de Souza; Sarah Stela Resende; Taís Nóbrega de Sousa; Cristiana Ferreira Alves de Brito
Journal:  Genet Mol Biol       Date:  2019-11-14       Impact factor: 1.771

10.  Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.

Authors:  Charles T Quinn; Omar Niss; Min Dong; Amanda Pfeiffer; Jennifer Korpik; Mary Reynaud; Holly Bonar; Theodosia A Kalfa; Luke R Smart; Punam Malik; Russell E Ware; Alexander A Vinks; Patrick T McGann
Journal:  Br J Haematol       Date:  2021-07-05       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.